Physician profile
Collyn Cunning
NPI 1902257280
$1,641.31
in general payments reported to CMS, 2019-2025
27 companies · $209 in 2025
The $209 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $293 · 2022: $288 · 2023: $397 · 2024: $454 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,060.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,059.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $277.25 | 2021-2025 | |
| Novo Nordisk INC | $186.03 | 2021-2024 | Wegovy |
| Pfizer INC. | $149.47 | 2021-2025 | |
| Glaxosmithkline, LLC. | $116.36 | 2022-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $100.43 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $89.46 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $84.77 | 2022-2024 | |
| Abbott Laboratories | $81.52 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Shield Therapeutics INC | $78.57 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $66.27 | 2022 | |
| Novartis Pharmaceuticals Corporation | $45.12 | 2023-2024 | |
| Seqirus USA INC | $39.01 | 2021-2024 | Flucelvax, Fluad |
| Dexcom, INC. | $38.86 | 2025 | Dexcom G6 Transmitter |
| Amgen INC. | $38.44 | 2023-2024 | Repatha, Otezla |
| Boston Scientific Corporation | $38.09 | 2023-2024 | Wavewriter Alpha Prime 16 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $24.68 | 2024 | Korlym |
| Daiichi Sankyo INC. | $23.37 | 2021 | |
| Idorsia Pharmaceuticals US INC | $21.35 | 2022 | |
| Axsome Therapeutics, INC. | $18.40 | 2025 | Symbravo |
| Phathom Pharmaceuticals, INC. | $18.36 | 2024 | Voquezna |
| Exact Sciences Corporation | $18.33 | 2025 | Cologuard Collection Kit |
| Paratek Pharmaceuticals, INC. | $17.01 | 2024 | Nuzyra |
| Astrazeneca Pharmaceuticals LP | $15.90 | 2021 | |
| Xeris Pharmaceuticals, INC. | $15.47 | 2021 | |
| Upsher-Smith Laboratories LLC | $15.16 | 2021 | |
| Vbi Vaccine (Delaware) INC. | $13.86 | 2022 | |
| Dynavax Technologies Corporation | $9.77 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Collyn Cunning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.